期刊文献+

[评论]T1期结直肠癌内镜切除后再行补充手术与直接手术治疗的远期疗效比较

[Comment]Long-term outcomes of additional surgery after endoscopic resection versus primary surgery for T1 colorectal cancer
下载PDF
导出
摘要 背景对于T1期结直肠癌,内镜切除后再行补充手术是否会造成肿瘤学上的不良影响备受关注。本研究旨在通过倾向性评分匹配分析,比较接受内镜切除后进行补充手术与直接手术治疗T1期结直肠癌患者的长期结局。方法本研究纳入了2009年至2016年间在日本27家大型医院接受内镜切除或外科切除的6105例T1期结直肠癌患者,其中单独接受手术的患者被纳入直接手术组,而在内镜切除后接受补充手术的患者被纳入补充手术组。采用倾向性评分匹配分析长期结果,包括死亡率和复发率。结果经过倾向性评分匹配后,两个组分别确定了1219例患者(共2438例)。补充手术组和直接手术组的5年总体生存率分别为97.1%和96.0%(风险比为0.72,95%CI为0.49~1.08),表明补充手术组的非劣效性。此外,补充手术组中有32例患者(2.6%)出现复发,而直接手术组中有24例(2.0%),两组之间比较差异没有统计学意义(比值比为1.34,95%CI为0.76~2.40,P=0.344)。讨论对于T1期结直肠癌患者,在补充手术之前进行内镜切除对患者的长期结局(包括5年总体生存率)没有不良影响。对于可切除的T期结直肠癌,内镜切除是一种可行的一线治疗选择。 Introduction There is considerable concern about whether endoscopic resection(ER)prior to additional surgery(AS)for T1 colorectal cancer(CRC)has oncologically potential adverse effects.Therefore,this study aimed to compare the long-term outcomes,including overall survival(OS),of patients treated with AS after ER versus primary surgery(PS)for T1 CRC using a propensity score-matched analysis from a large observational study.Methods This study investigated 6,105 patients with T1 CRC treated with either ER or surgical resection between 2009 and 2016 at 27 high-volume Japanese institutions,with those undergoing surgery alone included in the PS group and those undergoing AS after ER included in the AS group.Propensity score matching was used for long-term outcomes of mortality and recurrence analysis.Results After propensity score matching,1,219 of 2,438 patients were identified in each group.The 5-year OS rates in the AS and PS groups were 97.1%and 96.0%,respectively[hazard ratio(HR):0.72;95%confidence interval(CI):0.49-1.08],indicating the non-inferiority of the AS group.Moreover,32 patients(2.6%)in the AS group and 24(2.0%)in the PS group had recurrences,with no significant difference between the two groups[odds ratio(OR):1.34;95%CI:0.76-2.40;P=0.344).Discussion ER prior to AS for T1 CRC had no adverse effect on patients’long-term outcomes,including the 5-year OS rate.ER is a viable first-line treatment option for endoscopically resectable T1 CRC.
作者 张博翔 李建男 Zhang Boxiang;Li jiannan
出处 《结直肠肛门外科》 2024年第4期479-480,485,共3页 Journal of Colorectal & Anal Surgery
关键词 T1期 结直肠癌 总体生存 复发 内镜切除 T1 colorectal cancer overall survival recurrence endoscopic resection
  • 相关文献

参考文献1

  • 1中华人民共和国国家卫生健康委员会,中华医学会肿瘤学分会,顾晋,汪建平,王锡山,张苏展,蔡三军,李进,沈琳,徐瑞华,金晶,章真,梁智勇,孙应实,王晰程,刘骞,彭亦凡.中国结直肠癌诊疗规范(2023年版)[J].中华外科杂志,2023,61(8):617-644. 被引量:44

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部